Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized open-label active-controlled study of JKN23041 inhalation solution in moderate to severe COPD
CTR20243686Phase 2Completed
- Sponsor
- Beijing Shuobai Pharmaceutical Technology
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JKN23041 in chronic obstructive pulmonary disease (COPD), sponsored by Beijing Shuobai Pharmaceutical Technology. Started Oct 2024; status: completed.
02
Drugs
JKN23041
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20243686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243686.